ライフサイエンスコーパス: leuprolide

1 typically following parenteral injections of leuprolide.

2 in GDX mice improved by testosterone but not leuprolide.

3 e an apnoea was greater after treatment with leuprolide (2.56 +/- 0.25 versus 4.06 +/- 0.29 Torr; P =

4 d continued until disease progression; depot leuprolide 7.5 mg intramuscularly begun on day 5 and rep

5 en underwent administration of 18 or 36mg of leuprolide, a GnRH agonist and a larger MW peptide, via

6 nse of serum 17 alpha-hydroxyprogesterone to leuprolide, a gonadotrophin-releasing hormone agonist, a

7 eening, women received monthly injections of leuprolide acetate (3.75 mg) for 2-3 months.

8 d the gonadotropin-releasing hormone agonist leuprolide acetate (7.5 mg intramuscularly every 4 weeks

9 nd that adding the antiandrogen flutamide to leuprolide acetate (a synthetic gonadotropin-releasing h

10 or once-monthly intramuscular injections of leuprolide acetate (at a dose of 3.75 mg).

11 n via preconditioning treatment with KGF and leuprolide acetate (Lupron), 2 clinically approved agent

12 y the gonadotropin-releasing hormone agonist leuprolide acetate (Lupron), Lupron plus estradiol repla

13 Men received depot leuprolide acetate (Lupron, 7.5 mg intramuscularly) ever

14 stal acetate, and for 40% of those receiving leuprolide acetate (P<0.001 for each dose of ulipristal

15 h a 3-month course of NAAD that consisted of leuprolide acetate and flutamide before 3D-CRT.

16 olved after a short course of treatment with leuprolide acetate but returned after medication was dis

17 In vivo experiments on hairless rats with leuprolide acetate confirmed the potency and safety of o

18 ulipristal acetate as compared with those of leuprolide acetate for the treatment of symptomatic uter

19 tal acetate were noninferior to once-monthly leuprolide acetate in controlling uterine bleeding and w

20 Only combined treatment with KGF plus leuprolide acetate normalized TEC subset numbers and thy

21 g peptide solutions of 0.2-4mM octreotide or leuprolide acetate salts in a 0.1M HEPES buffer, pH7.4,

22 Leuprolide acetate treatment resulted in a 3.5-fold (p <

23 Androgen deprivation therapy with leuprolide acetate was initiated, and the addition of a

24 ng hormone-releasing hormone agonist (LHRHa; leuprolide acetate) does not reduce serum androgens as e

25 e acetate, for differences (as compared with leuprolide acetate) of 1.2 percentage points (95% confid

26 .001 for each dose of ulipristal acetate vs. leuprolide acetate).

27 demonstrate that sex steroid ablation using leuprolide acetate, a luteinizing hormone-releasing horm

28 ormed to evaluate the effectiveness of depot leuprolide acetate, a synthetic gonadotropin-releasing h

29 Leuprolide acetate, a synthetic nonapeptide analogue of

30 h the gonadotropin-releasing hormone agonist leuprolide acetate, adding back supraphysiologic doses o

31 istal acetate, and in 89% of those receiving leuprolide acetate, for differences (as compared with le

32 y the gonadotropin-releasing hormone agonist leuprolide acetate, leuprolide plus estradiol, and leupr

33 evaluation of drug delivery technologies for leuprolide acetate, one of the most time-consuming steps

34 In response to treatment with leuprolide acetate, the threshold measured in wakefulnes

35 dotropin releasing hormone analogue (GnRHa), leuprolide acetate, to suppress OE2 for 35 days, and the

36 ted C57Bl/6J mice with the anti-gonadotropin leuprolide acetate, which suppresses both sex steroids a

37 hod to rapidly assay the in vitro release of leuprolide acetate.

38 tal acetate, and 21 days for those receiving leuprolide acetate.

39 ompared with that achieved with placebo plus leuprolide acetate.

40 YC were offered treatment with GnRH-a (depot leuprolide acetate; a 3.75-mg monthly injection during t

41 the gonadotropin-releasing hormone agonist, leuprolide acetate; leuprolide plus estradiol; and leupr

42 esign, each for four weeks, during continued leuprolide administration.

43 were given placebo hormone during continued leuprolide administration.

44 cer and no bone metastases to receive either leuprolide alone or leuprolide and pamidronate (60 mg in

45 n symptom severity between the last month of leuprolide alone, placebo month, or second and third mon

46 In men treated with leuprolide alone, the mean (+/-SE) bone mineral density

47 progesterone compared with the last month of leuprolide alone, the placebo month, and the second and

48 udied the effect of ovarian suppression with leuprolide, an agonist analogue of gonadotropin-releasin

49 After 9 months of treatment with leuprolide and flutamide, androgen deprivation therapy (

50 rogen deprivation therapy (ADT) comprised of leuprolide and flutamide.

51 stases to receive either leuprolide alone or leuprolide and pamidronate (60 mg intravenously every 12

52 t any skeletal site in men treated with both leuprolide and pamidronate.

53 ost controlled-release injectable depots for leuprolide and related peptides.

54 ine 21-day cycles of docetaxel (70 mg/m(2)), leuprolide, and 3 days of testosterone.

55 six 28-day cycles of docetaxel (75 mg/m(2)), leuprolide, and 7 days of topical testosterone.

56 example, twice-a-year depot injections with leuprolide are available compared to the once-a-day inje

57 leasing hormone analogues (GnRHa; nafarelin, leuprolide, buserelin, goserelin, triptorelin), laparosc

58 Thus far, the dominant means for leuprolide detection involves conventional multistep hig

59 In contrast, leuprolide did not significantly decrease Abeta levels a

60 mechanistic signature of in vitro release of leuprolide for future comparison with corresponding in v

61 After the initial burst release, release of leuprolide from acid-capped PLGA microspheres appeared t

62 trolled pulsatile release of the polypeptide leuprolide from microchip implants over 6 months in dogs

63 Release of leuprolide from the end-capped PLGA showed similar trend

64 Fat mass increased by 11.1% +/- 1.3% in the leuprolide group and by 6.4% +/- 1.1% in the bicalutamid

65 mbar spine decreased by 2.5% +/- 0.5% in the leuprolide group and increased by 2.5 +/- 0.5 in the bic

66 common in the bicalutamide group than in the leuprolide group.

67 common in the bicalutamide group than in the leuprolide group.

68 en with premenstrual syndrome who were given leuprolide had a significant decrease in symptoms as com

69 e LHRH agonists, although CIs were wider for leuprolide (hazard ratio, 1.0994 [CI, 0.207 to 5.835]) a

70 ieve sustained and constant plasma levels of leuprolide, interferon alpha-2b, letrozole, Y-27632, oct

71 Importantly, absorption of leuprolide into low MW PLGA-COOH particles yielded ~17 w

72 of various incubation media on release from leuprolide-loaded PLGA microspheres to understand the in

73 low MW PLGA-COOH particles yielded ~17 wt.% leuprolide loading in the polymer (i.e., ~70% of PLGA-CO

74 ine (Tyr) amino acid residues present in the leuprolide nonapeptide, the in vitro release from liquid

75 Therapy with diethylstilbestrol (DES), leuprolide, or bilateral orchiectomy has been reported t

76 The release of sorbed peptide from leuprolide-PLGA particles was evaluated both in vitro (P

77 en with premenstrual syndrome who were given leuprolide plus estradiol or progesterone had a signific

78 eleasing hormone agonist leuprolide acetate, leuprolide plus estradiol, and leuprolide plus progester

79 leasing hormone agonist, leuprolide acetate; leuprolide plus estradiol; and leuprolide plus progester

80 lide acetate; leuprolide plus estradiol; and leuprolide plus progesterone.

81 lide acetate, leuprolide plus estradiol, and leuprolide plus progesterone.

82 e of continuous androgen ablation induced by Leuprolide, regression of the androgen-independent tumor

83 the detection and accurate quantification of leuprolide release from formulation candidates.

84 Here, we demonstrate that assaying leuprolide release using intrinsic protein fluorescence

85 per liter) (P = 0.01) and a reduction in the leuprolide-stimulated peak serum 17 alpha-hydroxyprogest

86 easing hormone (LHRH) analogs, Nafarelin and Leuprolide, that exhibit down-regulation of their own tr

87 of GnRH agonist-induced ovarian suppression (leuprolide) then received 1 month of single-blind (parti

88 d a gonadotrophin-releasing hormone agonist, Leuprolide, to induce androgen ablation demonstrated sim

89 demarcated the threshold was decreased after leuprolide treatment (42.1 +/- 0.6 versus 39.6 +/- 0.6 T

90 Ten women whose symptoms improved during leuprolide treatment were given estradiol and progestero

91 LGA 50/50 microspheres encapsulating ~5% w/w leuprolide were prepared by the double emulsion-solvent

92 h the gonadotropin-releasing hormone agonist leuprolide, which inhibits the hypothalamic-pituitary-go